

Appendix to slide42-48: The number of patients in each group and crude survival probabilities at 1, 5, and 10 years after transplantation.

Slide42. Survival after Transplants by Transplant Type, 1991-2022

	Years after the first transplantation	N	OS	95% C.I.
Auto	At transplantation	40,746		
	1 year	31,211	84.6%	84.3 - 85.0%
	5 years	15,233	63.5%	63.0 - 64.0%
	10 years	6,091	52.0%	51.3 - 52.6%
Allo	At transplantation	66,697		
	1 year	40,932	65.6%	65.3 - 66.0%
	5 years	21,702	49.8%	49.4 - 50.2%
	10 years	10,567	45.2%	44.7 - 45.6%

Slide43. Survival after Transplants by Donor Type and Stem Cell Sources, 1991-2022

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	12,335		
	1 year	8,902	74.1%	73.3 - 74.9%
	5 years	5,888	58.9%	58.0 - 59.8%
	10 years	3,712	55.0%	54.0 - 55.9%
Rel-PB	At transplantation	13,584		
	1 year	7,796	62.3%	61.5 - 63.1%
	5 years	3,366	43.3%	42.4 - 44.2%
	10 years	1,449	37.7%	36.7 - 38.6%
UR-BM	At transplantation	22,530		
	1 year	14,301	67.4%	66.7 - 68.0%
	5 years	8,083	51.7%	51.0 - 52.4%
	10 years	3,779	46.8%	46.0 - 47.5%
UR-PB	At transplantation	1,499		
	1 year	883	72.0%	69.6 - 74.3%
	5 years	178	54.6%	51.5 - 57.6%
	10 years	8	46.5%	41.1 - 51.6%
UR-CB	At transplantation	16,749		
	1 year	9,049	59.1%	58.3 - 59.8%
	5 years	4,183	44.8%	44.0 - 45.6%
	10 years	1,617	40.5%	39.7 - 41.4%

Slide44. Survival after Transplants for Leukemia, 1991-2022

	Years after the first transplantation	N	OS	95% C.I.
AML	At transplantation	26,970		
	1 year	16,194	64.3%	63.7 - 64.9%
	5 years	8,060	46.4%	45.8 - 47.1%
	10 years	3,716	41.7%	41.1 - 42.4%
ALL	At transplantation	13,942		
	1 year	9,410	71.8%	71.1 - 72.6%
	5 years	4,995	52.9%	52.1 - 53.8%
	10 years	2,540	48.5%	47.5 - 49.4%
ATL	At transplantation	2,999		
	1 year	1,327	47.5%	45.7 - 49.3%
	5 years	592	31.8%	30.1 - 33.6%
	10 years	224	26.2%	24.3 - 28.0%
CML	At transplantation	3,855		
	1 year	2,653	71.6%	70.1 - 73.0%
	5 years	1,845	59.6%	58.0 - 61.1%
	10 years	1,166	55.3%	53.6 - 57.0%
MDS	At transplantation	7,560		
	1 year	4,613	66.0%	64.9 - 67.1%
	5 years	2,209	49.1%	47.9 - 50.3%
	10 years	896	42.4%	41.1 - 43.8%

Slide45. Survival after Transplants for Malignant Lymphoma and MM/PCD, 1991-2022

	Years after the first transplantation	N	OS	95% C.I.
NHL	At transplantation	23,243		
	1 year	15,508	73.6%	73.0 - 74.1%
	5 years	8,072	58.2%	57.5 - 58.8%
	10 years	3,386	50.5%	49.7 - 51.3%
HL	At transplantation	1,810		
	1 year	1,437	87.3%	85.7 - 88.8%
	5 years	737	71.0%	68.6 - 73.3%
	10 years	272	63.8%	60.9 - 66.5%
Other lymphoma / type missing	At transplantation	599		
	1 year	370	70.9%	66.9 - 74.5%
	5 years	197	54.3%	49.8 - 58.7%
	10 years	116	46.1%	41.3 - 50.8%
MM/PCD	At transplantation	13,097		
	1 year	10,780	92.8%	92.3 - 93.3%
	5 years	4,534	66.9%	65.9 - 67.8%
	10 years	1,188	44.4%	43.1 - 45.7%

Slide46. Survival after Autologous Transplants for Acute Leukemia, 1991-2022

	Years after the first transplantation	N	OS	95% C.I.
AML : Age ≤ 15	At transplantation	235		
	1 year	204	86.8%	81.8 - 90.5%
	5 years	147	64.2%	57.7 - 70.0%
	10 years	111	61.5%	54.9 - 67.4%
AML : Age ≥ 16	At transplantation	1,546		
	1 year	1,214	83.8%	81.8 - 85.6%
	5 years	738	68.2%	65.7 - 70.6%
	10 years	371	64.5%	61.8 - 67.1%
ALL : Age ≤ 15	At transplantation	393		
	1 year	320	81.4%	77.2 - 84.9%
	5 years	230	59.7%	54.6 - 64.3%
	10 years	155	55.4%	50.3 - 60.2%
ALL : Age ≥ 16	At transplantation	350		
	1 year	212	61.5%	56.2 - 66.4%
	5 years	95	32.0%	27.0 - 37.0%
	10 years	55	27.2%	22.4 - 32.2%

Slide47. Survival after Autologous Transplants for Malignant Lymphoma, 1991-2022

	Years after the first transplantation	N	OS	95% C.I.
NHL : Age ≤ 15	At transplantation	226		
	1 year	176	78.6%	72.7 - 83.5%
	5 years	141	71.3%	64.9 - 76.8%
	10 years	100	70.7%	64.2 - 76.2%
NHL : Age ≥ 16	At transplantation	17,286		
	1 year	12,386	79.8%	79.1 - 80.4%
	5 years	6,275	62.9%	62.1 - 63.7%
	10 years	2,501	53.6%	52.6 - 54.5%
HL : Age ≤ 15	At transplantation	38		
	1 year	33	86.8%	71.2 - 94.3%
	5 years	16	75.2%	57.6 - 86.3%
	10 years	9	75.2%	57.6 - 86.3%
HL : Age ≥ 16	At transplantation	1,599		
	1 year	1,297	89.9%	88.3 - 91.3%
	5 years	671	73.6%	71.1 - 75.9%
	10 years	243	66.2%	63.1 - 69.1%

Slide48. Survival after Autologous Transplants for MM/PCD, 1991-2022 (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
MM / PCD	At transplantation	12,752		
	1 year	10,613	94.0%	93.6 - 94.4%
	5 years	4,464	68.0%	67.1 - 69.0%
	10 years	1,152	45.1%	43.7 - 46.5%

Appendix to slide49-92: The number of patients in each group and crude survival probabilities at 1, 5 years after transplantation.

Slide49. Survival after Allogeneic Transplants for AML, 2013-2022 (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	161		
	1 year	116	76.6%	69.1 - 82.4%
	5 years	50	61.6%	53.1 - 69.0%
Rel-PB	At transplantation	104		
	1 year	71	73.4%	63.6 - 80.9%
	5 years	21	48.7%	37.9 - 58.7%
UR-BM	At transplantation	140		
	1 year	103	79.8%	71.9 - 85.7%
	5 years	41	65.8%	56.6 - 73.5%
UR-CB	At transplantation	281		
	1 year	207	81.7%	76.5 - 85.8%
	5 years	77	59.1%	52.4 - 65.2%

Slide50. Survival after Allogeneic Transplants for AML, 2013-2022 (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	549		
	1 year	379	74.4%	70.5 - 77.9%
	5 years	155	56.5%	51.9 - 60.8%
Rel-PB	At transplantation	2,877		
	1 year	1,670	65.5%	63.7 - 67.3%
	5 years	474	45.0%	42.9 - 47.1%
UR-BM	At transplantation	3,122		
	1 year	1,874	67.4%	65.6 - 69.0%
	5 years	751	49.8%	47.9 - 51.8%
UR-CB	At transplantation	4,401		
	1 year	2,365	60.8%	59.3 - 62.3%
	5 years	713	44.2%	42.5 - 45.8%

Slide51. Survival after Allogeneic Transplants for AML, 2013-2022 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	63		
	1 year	56	92.0%	81.7 - 96.6%
	5 years	23	73.3%	59.4 - 83.0%
Advanced risk	At transplantation	31		
	1 year	17	57.2%	37.9 - 72.5%
	5 years	9	46.5%	28.1 - 63.0%

Slide52. Survival after Allogeneic Transplants for AML, 2013-2022 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	1,230		
	1 year	942	83.9%	81.6 - 85.8%
	5 years	324	63.6%	60.4 - 66.5%
Advanced risk	At transplantation	601		
	1 year	261	47.7%	43.6 - 51.7%
	5 years	78	28.0%	24.1 - 32.1%

Slide53. Survival after Allogeneic Transplants for AML, 2013-2022 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	93		
	1 year	79	92.1%	84.2 - 96.2%
	5 years	34	77.8%	67.0 - 85.5%
Advanced risk	At transplantation	47		
	1 year	24	55.9%	40.3 - 68.9%
	5 years	7	42.0%	26.7 - 56.5%

Slide54. Survival after Allogeneic Transplants for AML, 2013-2022 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	2,133		
	1 year	1,484	78.6%	76.7 - 80.3%
	5 years	607	60.9%	58.5 - 63.1%
Advanced risk	At transplantation	979		
	1 year	384	42.9%	39.7 - 46.1%
	5 years	143	26.2%	23.2 - 29.2%

Slide55. Survival after Allogeneic Transplants for AML, 2013-2022 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	181		
	1 year	159	96.0%	91.7 - 98.1%
	5 years	62	76.1%	68.2 - 82.4%
Advanced risk	At transplantation	98		
	1 year	47	55.2%	44.3 - 64.8%
	5 years	14	27.5%	18.2 - 37.6%

Slide56. Survival after Allogeneic Transplants for AML, 2013-2022 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	2,164		
	1 year	1,443	76.2%	74.3 - 78.0%
	5 years	448	61.0%	58.6 - 63.3%
Advanced risk	At transplantation	2,235		
	1 year	920	46.0%	43.9 - 48.1%
	5 years	264	28.4%	26.3 - 30.5%

Slide57. Survival after Allogeneic Transplants for ALL, 2013-2022 (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	202		
	1 year	156	84.1%	78.1 - 88.5%
	5 years	64	69.5%	62.0 - 75.9%
Rel-PB	At transplantation	113		
	1 year	61	58.0%	48.3 - 66.5%
	5 years	20	42.8%	33.2 - 52.0%
UR-BM	At transplantation	212		
	1 year	169	87.8%	82.5 - 91.6%
	5 years	65	72.3%	64.8 - 78.5%
UR-CB	At transplantation	358		
	1 year	268	85.2%	80.9 - 88.5%
	5 years	127	73.8%	68.5 - 78.4%

Slide59. Survival after Allogeneic Transplants for ALL, 2013-2022 <HLA-identical Sibling> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	58		
	1 year	47	94.5%	84.0 - 98.2%
	5 years	23	87.5%	74.0 - 94.2%
Advanced risk	At transplantation	60		
	1 year	44	76.2%	63.1 - 85.1%
	5 years	13	54.5%	39.2 - 67.4%

Slide62. Survival after Allogeneic Transplants for ALL, 2013-2022 <UR-BM> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	1,196		
	1 year	909	85.1%	82.9 - 87.0%
	5 years	365	68.6%	65.5 - 71.4%
Advanced risk	At transplantation	342		
	1 year	170	60.2%	54.6 - 65.4%
	5 years	51	37.1%	31.2 - 43.0%

Slide58. Survival after Allogeneic Transplants for ALL, 2013-2022 (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	292		
	1 year	234	87.3%	82.8 - 90.7%
	5 years	93	68.0%	61.5 - 73.6%
Rel-PB	At transplantation	1,108		
	1 year	774	79.7%	77.1 - 82.0%
	5 years	214	59.0%	55.5 - 62.4%
UR-BM	At transplantation	1,538		
	1 year	1,078	79.7%	77.5 - 81.7%
	5 years	416	61.7%	58.9 - 64.4%
UR-CB	At transplantation	1,267		
	1 year	810	73.7%	71.1 - 76.1%
	5 years	264	58.3%	55.2 - 61.3%

Slide60. Survival after Allogeneic Transplants for ALL, 2013-2022 <HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	655		
	1 year	548	92.0%	89.6 - 93.9%
	5 years	208	73.1%	69.0 - 76.8%
Advanced risk	At transplantation	179		
	1 year	118	69.8%	62.4 - 76.0%
	5 years	26	40.8%	32.2 - 49.3%

Slide63. Survival after Allogeneic Transplants for ALL, 2013-2022 <UR-CB> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	163		
	1 year	135	91.6%	86.0 - 95.1%
	5 years	74	83.5%	76.1 - 88.8%
Advanced risk	At transplantation	195		
	1 year	134	79.7%	73.2 - 84.8%
	5 years	54	65.7%	57.8 - 72.4%

Slide61. Survival after Allogeneic Transplants for ALL, 2013-2022 <UR-BM> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	109		
	1 year	96	97.0%	91.0 - 99.0%
	5 years	42	87.9%	79.2 - 93.2%
Advanced risk	At transplantation	103		
	1 year	73	78.1%	68.7 - 85.0%
	5 years	23	55.4%	43.6 - 65.8%

Slide64. Survival after Allogeneic Transplants for ALL, 2013-2022 <UR-CB> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	824		
	1 year	597	83.1%	80.3 - 85.6%
	5 years	211	71.4%	67.8 - 74.7%
Advanced risk	At transplantation	442		
	1 year	211	56.0%	51.1 - 60.7%
	5 years	52	33.1%	28.0 - 38.3%

**Slide65. Survival after Allogeneic Transplants for CML, 2013-2022
(Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM / Rel-PB	At transplantation	14		
	1 year	11	78.6%	47.3 - 92.5%
	5 years	10	78.6%	47.3 - 92.5%
UR-BM	At transplantation	12		
	1 year	10	83.3%	48.2 - 95.6%
	5 years	7	75.0%	40.8 - 91.2%
UR-CB	At transplantation	7		
	1 year	7	100.0%	
	5 years	2	100.0%	

**Slide66. Survival after Allogeneic Transplants for CML, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	34		
	1 year	28	93.4%	76.2 - 98.3%
	5 years	11	85.4%	65.0 - 94.4%
Rel-PB	At transplantation	174		
	1 year	123	80.5%	73.6 - 85.8%
	5 years	37	63.0%	53.9 - 70.8%
UR-BM	At transplantation	229		
	1 year	159	80.5%	74.6 - 85.2%
	5 years	71	69.5%	62.4 - 75.5%
UR-CB	At transplantation	181		
	1 year	119	74.8%	67.7 - 80.6%
	5 years	58	68.9%	61.2 - 75.5%

**Slide67. Survival after Allogeneic Transplants for CML, 2013-2022
<HLA-identical Sibling> (Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	46		
	1 year	40	95.2%	82.3 - 98.8%
	5 years	12	84.9%	65.8 - 93.8%
Advanced risk	At transplantation	80		
	1 year	60	82.8%	72.3 - 89.7%
	5 years	21	62.4%	49.6 - 72.9%

**Slide68. Survival after Allogeneic Transplants for CML, 2013-2022
<UR-BM> (Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	94		
	1 year	66	82.8%	73.1 - 89.3%
	5 years	28	77.6%	67.0 - 85.1%
Advanced risk	At transplantation	135		
	1 year	93	78.9%	70.8 - 85.1%
	5 years	43	64.2%	54.4 - 72.3%

**Slide69. Survival after Allogeneic Transplants for CML, 2013-2022
<UR-CB> (Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	55		
	1 year	43	88.7%	76.6 - 94.8%
	5 years	11	83.7%	69.7 - 91.6%
Advanced risk	At transplantation	126		
	1 year	76	68.7%	59.6 - 76.2%
	5 years	47	62.8%	53.3 - 70.9%

**Slide70. Survival after Allogeneic Transplants for MDS, 2013-2022
(Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	64		
	1 year	57	93.7%	83.9 - 97.6%
	5 years	31	90.2%	79.4 - 95.5%
Rel-PB	At transplantation	14		
	1 year	10	84.6%	51.2 - 95.9%
	5 years	4	76.2%	42.7 - 91.7%
UR-BM	At transplantation	115		
	1 year	95	92.0%	85.1 - 95.7%
	5 years	43	80.1%	70.3 - 87.0%
UR-CB	At transplantation	42		
	1 year	33	87.8%	73.0 - 94.7%
	5 years	14	75.3%	57.2 - 86.5%

**Slide71. Survival after Allogeneic Transplants for MDS, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	204		
	1 year	132	68.4%	61.5 - 74.4%
	5 years	53	48.0%	40.4 - 55.2%
Rel-PB	At transplantation	821		
	1 year	468	65.8%	62.4 - 69.0%
	5 years	135	49.1%	45.1 - 53.0%
UR-BM	At transplantation	1,529		
	1 year	932	67.5%	65.1 - 69.9%
	5 years	305	46.7%	43.8 - 49.5%
UR-CB	At transplantation	1,158		
	1 year	637	62.4%	59.5 - 65.2%
	5 years	190	45.8%	42.5 - 49.1%

**Slide72. Survival after Allogeneic Transplants for MDS, 2013-2022
<HLA-identical Sibling> (Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	40		
	1 year	36	92.4%	78.3 - 97.5%
	5 years	20	92.4%	78.3 - 97.5%
Advanced risk	At transplantation	7		
	1 year	7	100.0%	
	5 years	5	71.4%	25.8 - 92.0%

**Slide75. Survival after Allogeneic Transplants for MDS, 2013-2022
<UR-BM> (Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	540		
	1 year	353	71.6%	67.5 - 75.3%
	5 years	134	52.2%	47.3 - 56.7%
Advanced risk	At transplantation	943		
	1 year	549	64.8%	61.5 - 67.8%
	5 years	168	43.2%	39.6 - 46.7%

**Slide78. Survival after Allogeneic Transplants for NHL, 2013-2022
(Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	22		
	1 year	16	77.3%	53.7 - 89.9%
	5 years	6	72.4%	48.6 - 86.6%
Rel-PB	At transplantation	20		
	1 year	12	60.0%	35.7 - 77.6%
	5 years	4	46.3%	22.4 - 67.3%
UR-BM	At transplantation	31		
	1 year	22	79.7%	60.2 - 90.3%
	5 years	7	69.2%	46.3 - 83.9%
UR-CB	At transplantation	42		
	1 year	26	73.2%	56.8 - 84.2%
	5 years	12	73.2%	56.8 - 84.2%

**Slide73. Survival after Allogeneic Transplants for MDS, 2013-2022
<HLA-identical Sibling> (Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	189		
	1 year	132	75.0%	68.1 - 80.7%
	5 years	58	64.0%	56.3 - 70.7%
Advanced risk	At transplantation	334		
	1 year	197	65.7%	60.2 - 70.7%
	5 years	70	45.7%	39.6 - 51.6%

**Slide76. Survival after Allogeneic Transplants for MDS, 2013-2022
<UR-CB> (Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	17		
	1 year	12	82.4%	54.7 - 93.9%
	5 years	6	73.2%	42.0 - 89.4%
Advanced risk	At transplantation	20		
	1 year	16	89.2%	63.2 - 97.2%
	5 years	7	72.0%	45.2 - 87.3%

**Slide79. Survival after Allogeneic Transplants for NHL, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	106		
	1 year	62	64.1%	54.0 - 72.6%
	5 years	23	53.8%	43.4 - 63.2%
Rel-PB	At transplantation	787		
	1 year	374	53.2%	49.6 - 56.7%
	5 years	107	41.1%	37.2 - 44.8%
UR-BM	At transplantation	547		
	1 year	319	63.8%	59.5 - 67.7%
	5 years	150	50.2%	45.7 - 54.6%
UR-CB	At transplantation	873		
	1 year	396	51.1%	47.7 - 54.5%
	5 years	157	40.6%	37.1 - 44.1%

**Slide74. Survival after Allogeneic Transplants for MDS, 2013-2022
<UR-BM> (Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	78		
	1 year	68	97.3%	89.7 - 99.3%
	5 years	40	89.1%	78.4 - 94.7%
Advanced risk	At transplantation	27		
	1 year	21	88.9%	69.4 - 96.3%
	5 years	3	63.8%	37.3 - 81.5%

**Slide77. Survival after Allogeneic Transplants for MDS, 2013-2022
<UR-CB> (Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Standard risk	At transplantation	354		
	1 year	216	68.1%	62.9 - 72.8%
	5 years	59	52.0%	45.9 - 57.7%
Advanced risk	At transplantation	779		
	1 year	412	60.0%	56.4 - 63.4%
	5 years	130	43.1%	39.1 - 47.1%

Slide80. Survival after Allogeneic Transplants for NHL, 2013-2022
<HLA-identical Sibling> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
1CR	At transplantation	95		
	1 year	80	89.2%	80.9 - 94.0%
	5 years	22	71.7%	59.9 - 80.6%
2CR	At transplantation	40		
	1 year	31	84.8%	69.2 - 92.9%
	5 years	15	84.8%	69.2 - 92.9%
≥3CR	At transplantation	17		
	1 year	16	94.1%	65.0 - 99.2%
	5 years	6	80.7%	51.1 - 93.4%
1PR	At transplantation	48		
	1 year	31	72.1%	56.7 - 82.7%
	5 years	9	53.3%	36.9 - 67.2%
2PR	At transplantation	48		
	1 year	31	66.3%	51.0 - 77.8%
	5 years	16	56.6%	40.9 - 69.6%
NIR	At transplantation	185		
	1 year	70	40.1%	32.9 - 47.1%
	5 years	25	29.1%	22.4 - 36.1%

Slide83. Survival after Allogeneic Transplants for NHL, 2013-2022
<UR-CB> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
CR / PR	At transplantation	26		
	1 year	18	84.1%	63.1 - 93.7%
	5 years	8	84.1%	63.1 - 93.7%
NIR	At transplantation	16		
	1 year	8	55.6%	28.6 - 75.9%
	5 years	4	55.6%	28.6 - 75.9%

Slide81. Survival after Allogeneic Transplants for NHL, 2013-2022
<UR-BM> (Age≤15)

	Years after the first transplantation	N	OS	95% C.I.
CR / PR	At transplantation	17		
	1 year	10	67.9%	38.9 - 85.3%
	5 years	3	59.4%	30.2 - 79.7%
NIR	At transplantation	14		
	1 year	12	92.9%	59.1 - 99.0%
	5 years	4	77.4%	31.5 - 94.5%

Slide84. Survival after Allogeneic Transplants for NHL, 2013-2022
<UR-CB> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
1CR	At transplantation	136		
	1 year	86	71.4%	62.9 - 78.3%
	5 years	30	56.3%	46.4 - 65.1%
2CR	At transplantation	91		
	1 year	50	64.6%	53.6 - 73.7%
	5 years	23	58.9%	47.6 - 68.7%
≥3CR	At transplantation	23		
	1 year	16	78.0%	55.0 - 90.2%
	5 years	10	72.0%	47.5 - 86.5%
1PR	At transplantation	108		
	1 year	51	57.8%	47.5 - 66.8%
	5 years	18	50.6%	40.2 - 60.1%
2PR	At transplantation	85		
	1 year	34	44.3%	33.4 - 54.7%
	5 years	16	36.0%	25.6 - 46.5%
NIR	At transplantation	429		
	1 year	157	40.0%	35.3 - 44.7%
	5 years	60	29.0%	24.5 - 33.6%

Slide82. Survival after Allogeneic Transplants for NHL, 2013-2022
<UR-BM> (Age≥16)

	Years after the first transplantation	N	OS	95% C.I.
1CR	At transplantation	128		
	1 year	90	77.8%	69.5 - 84.1%
	5 years	43	63.4%	53.8 - 71.5%
2CR	At transplantation	64		
	1 year	51	82.5%	70.7 - 89.9%
	5 years	27	64.5%	50.6 - 75.4%
≥3CR	At transplantation	40		
	1 year	27	69.8%	52.9 - 81.6%
	5 years	18	58.7%	41.6 - 72.4%
1PR	At transplantation	56		
	1 year	31	63.5%	49.2 - 74.7%
	5 years	9	44.4%	29.4 - 58.3%
2PR	At transplantation	66		
	1 year	40	67.0%	53.9 - 77.1%
	5 years	19	53.7%	40.1 - 65.5%
NIR	At transplantation	193		
	1 year	80	45.8%	38.5 - 52.7%
	5 years	35	35.3%	28.2 - 42.4%

**Slide85. Survival after Autologous Transplants for MM / PCD, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
MM / PCD	At transplantation	7,790		
	1 year	6,286	95.6%	95.1 - 96.1%
	5 years	2,061	76.0%	74.7 - 77.2%

**Slide86. Survival after Allogeneic Transplants for MM / PCD, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM / Rel-PB	At transplantation	29		
	1 year	11	37.9%	20.9 - 54.9%
	5 years	3	30.7%	15.2 - 47.7%
UR-BM	At transplantation	21		
	1 year	10	47.6%	25.7 - 66.7%
	5 years	4	29.0%	10.7 - 50.5%
UR-CB	At transplantation	17		
	1 year	4	29.1%	9.4 - 52.6%
	5 years	1	14.6%	1.2 - 43.2%

**Slide87. Survival after Autologous Transplants for MM / PCD, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR)	At transplantation	1,765		
	1 year	1,425	98.0%	97.2 - 98.6%
	5 years	393	80.7%	78.0 - 83.2%
VGPR	At transplantation	2,487		
	1 year	1,980	96.8%	95.9 - 97.4%
	5 years	602	76.6%	74.2 - 78.8%
PR	At transplantation	2,534		
	1 year	2,100	95.3%	94.4 - 96.1%
	5 years	789	73.7%	71.5 - 75.8%
SD	At transplantation	194		
	1 year	160	90.8%	85.6 - 94.2%
	5 years	57	60.5%	52.1 - 67.8%
PD / Rel	At transplantation	153		
	1 year	81	64.4%	55.8 - 71.7%
	5 years	20	34.7%	25.8 - 43.8%

**Slide88. Survival after Allogeneic Transplants for MM / PCD, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
CR (including sCR) / VGPR / PR	At transplantation	43		
	1 year	21	53.8%	37.4 - 67.6%
	5 years	6	34.3%	17.6 - 51.6%
SD / PD / Rel	At transplantation	23		
	1 year	3	13.0%	3.3 - 29.7%
	5 years	1	8.7%	1.5 - 24.2%

**Slide89. Survival after Allogeneic Transplants for AA, 2013-2022
(Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	121		
	1 year	103	97.3%	91.9 - 99.1%
	5 years	39	96.4%	90.6 - 98.6%
Rel-PB	At transplantation	7		
	1 year	5	85.7%	33.4 - 97.9%
	5 years	3	85.7%	33.4 - 97.9%
UR-BM	At transplantation	129		
	1 year	109	96.0%	90.5 - 98.3%
	5 years	50	95.0%	89.1 - 97.7%
UR-CB	At transplantation	28		
	1 year	21	100.0%	
	5 years	9	100.0%	

**Slide91. Survival after Allogeneic Transplants for AA, 2013-2022
(Age≤15)**

	Years after the first transplantation	N	OS	95% C.I.
HLA-identical Sibling	At transplantation	91		
	1 year	74	97.6%	90.8 - 99.4%
	5 years	31	97.6%	90.8 - 99.4%
UR-BM	At transplantation	129		
	1 year	109	96.0%	90.5 - 98.3%
	5 years	50	95.0%	89.1 - 97.7%
UR-CB	At transplantation	28		
	1 year	21	100.0%	
	5 years	9	100.0%	

**Slide90. Survival after Allogeneic Transplants for AA, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
Rel-BM	At transplantation	182		
	1 year	156	92.7%	87.7 - 95.7%
	5 years	63	87.5%	81.2 - 91.8%
Rel-PB	At transplantation	86		
	1 year	55	77.2%	66.5 - 84.8%
	5 years	19	69.9%	57.5 - 79.2%
UR-BM	At transplantation	229		
	1 year	171	81.3%	75.6 - 85.8%
	5 years	83	74.4%	67.9 - 79.7%
UR-CB	At transplantation	123		
	1 year	84	72.3%	63.4 - 79.3%
	5 years	35	70.3%	61.2 - 77.6%

**Slide92. Survival after Allogeneic Transplants for AA, 2013-2022
(Age≥16)**

	Years after the first transplantation	N	OS	95% C.I.
HLA-identical Sibling	At transplantation	183		
	1 year	152	89.4%	83.9 - 93.1%
	5 years	65	84.5%	77.9 - 89.2%
UR-BM	At transplantation	229		
	1 year	171	81.3%	75.6 - 85.8%
	5 years	83	74.4%	67.9 - 79.7%
UR-CB	At transplantation	123		
	1 year	84	72.3%	63.4 - 79.3%
	5 years	35	70.3%	61.2 - 77.6%